Olema Oncology to Present at Oppenheimer 33rd Annual Healthcare Conference

Rhea-AI Summary

Olema Pharmaceuticals, Nasdaq: OLMA, announced that CEO Sean Bohen will present at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 2:40 p.m. ET. A live webcast of this event will be accessible on Olema's investor relations website, and it will remain archived for 30 days. Olema focuses on developing targeted therapies for women's cancers, with its lead candidate OP-1250, an oral small molecule, currently in a Phase 2 trial for ER+/HER2- breast cancer. OP-1250 has received FDA Fast Track designation for patients who have not responded to prior endocrine therapy.

SAN FRANCISCO, March 02, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that Sean Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the Oppenheimer 33^rd Annual Healthcare Conference on Wednesday, March 15, 2023, at 2:40 p.m. ET.

A live webcast of the virtual presentation and any accompanying presentation materials will be available under the News & Events section of Olema’s investor relations website at www.olema.com. The webcast will be archived for at least 30 days.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated both as a single agent in an ongoing Phase 2 clinical trial, and in combination with CDK 4/6 inhibitors (palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. OP-1250 has been granted FDA Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. 

IR Contact:
Courtney Dugan, Vice President, Investor Relations and Communications
ir@olema.com

Media Contact:
Ignacio Guerrero-Ros, Ph.D., Russo Partners
646-942-5604
ignacio.guerrero-ros@russopartnersllc.com

FAQ

When is Sean Bohen presenting at the Oppenheimer Healthcare Conference?

Sean Bohen will present on March 15, 2023, at 2:40 p.m. ET.

Where can I watch the Olema Pharmaceuticals presentation?

The presentation will be available on Olema's investor relations website and archived for 30 days.

What is Olema Pharmaceuticals' lead product candidate?

Olema's lead product candidate is OP-1250, designed for treating ER+/HER2- breast cancer.

What FDA designation has OP-1250 received?

OP-1250 has been granted FDA Fast Track designation.

What type of company is Olema Pharmaceuticals?

Olema is a clinical-stage biopharmaceutical company focused on women's cancers.